New Biopharmaceuticals Factory Novo Nordisk Builds New Biopharmaceuticals Factory in Denmark
Novo Nordisk recently announced plans to build a new biopharmaceuticals factory in Kalundborg, Denmark, for around 1 billion Danish Kroner (EUR 134 million or US $ 191 million). The new factory shall produce biopharmaceuticals such as haemophilia medicine, growth hormone and other current and future pharmaceuticals beginning in 2013.
Bagsværd/Denmark – Plans to build up a new production in Kalundborg have circulated since last year's June. With the approval of Novo Nordisk's board, they become official: the Danish pharmaceuticals specialists invest around EUR 134 million in the site. Groundbreaking is scheduled for August 22nd. Packaging lines at Kalundborg are expected to be operational in 2013. The production of pharmaceuticals, nevertheless will not be approved and in operation until 2015 due to it's prolonged running-in period.
“We need to expand our production capacity to meet the future demand for our existing products, but also to be ready to produce future haemophilia products that are in the pipeline,” said Per Valstorp, senior vice president, Product Supply, Novo Nordisk. The new factory will cover formulation, freeze-drying, filling and packaging of a range of Novo Nordisk’s biopharmaceuticals, including NovoSeven haemophilia medicine, Norditropin growth hormone and the glucagon product GlucaGen.
Novo Nordisk thereby confirms it's commitment to Denmark as its location of industry: “We already have similar production in Gentofte, Denmark, and have built up great expertise in the production of biopharmaceuticals in Denmark. We were therefore never in doubt that this new factory should be placed in Denmark,” Valstorp added.